Patent ID: 6566398
Filing Date: 2003-05-20
Classification: A61K,A61P

Abstract:
A method for treatment of external secretion disorders, which comprises administering an effective amount of a prostaglandin compound to a subject in need of said treatment, provided that the prostaglandin is not prostaglandin E1,wherein the prostaglandin compound is the one represented by the general formula (I); â€ƒwherein W1, W2 and W3 are carbon atom, Lâ€², Mâ€² and Nâ€² are hydrogen, hydroxy, halogen, lower alkyl, hydroxy (lower)alkyl, or oxo, wherein at least one of Lâ€² and Mâ€² is a group other than hydrogen, and the five-membered ring may have at least one double bond, and wherein  is a single bond when Lâ€², Mâ€² and Nâ€² are hydrogen, hydroxy, halogen, lower alkyl, or hydroxy (lower)alkyl, and  is a double bond when Lâ€², Mâ€² and Nâ€² are oxo; A is â€”CH2OH, â€”COCH2OH, â€”COOH or its functional derivative; Bâ€² is single bond, â€”CH2â€”CH2â€”, â€”CH&boxH;CHâ€”, â€”Câ‰¡Câ€”, â€”CH2â€”CH2â€”CH2â€”, â€”CH&boxH;CHâ€”CH2â€”, â€”CH2â€”CH&boxH;CHâ€”, â€”Câ‰¡Câ€”CH2â€”, or â€”CH2â€”Câ‰¡Câ€”; Z is wherein R4 and R5 are hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or hydroxy (lower)alkyl, wherein R4 and R5 are not hydroxy and lower alkoxy at the same time; R1 is a divalent saturated or unsaturated lower-medium aliphatic hydrocarbon residue, which is unsubstituted or substituted by halogen, oxo, hydroxy, lower alkyl, aryl or heterocyclic; and Ra is a saturated or unsaturated lower-medium aliphatic hydrocarbon residue, which is unsubstituted or substituted by halogen, oxo, lower alkyl, hydroxy, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, cyclo(lower)alkyloxy, aryl, aryloxy, heterocyclic or heterocyclic-oxy; cyclo(lower)alkyl; cyclo(lower)alkyloxy; aryl; aryloxy; heterocyclic; or heterocyclic-oxy.